These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 7903100

  • 1. Engineering Fab' fragments for efficient F(ab)2 formation in Escherichia coli and for improved in vivo stability.
    Rodrigues ML, Snedecor B, Chen C, Wong WL, Garg S, Blank GS, Maneval D, Carter P.
    J Immunol; 1993 Dec 15; 151(12):6954-61. PubMed ID: 7903100
    [Abstract] [Full Text] [Related]

  • 2. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML, Shalaby MR, Werther W, Presta L, Carter P.
    Int J Cancer Suppl; 1992 Dec 15; 7():45-50. PubMed ID: 1428403
    [Abstract] [Full Text] [Related]

  • 3. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli].
    Xiong DS, Zheng MJ, Liu YX, Xu YF, Wang JH, Yang CZ.
    Sheng Wu Gong Cheng Xue Bao; 2004 Sep 15; 20(5):673-8. PubMed ID: 15973988
    [Abstract] [Full Text] [Related]

  • 4. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
    Glennie MJ, McBride HM, Worth AT, Stevenson GT.
    J Immunol; 1987 Oct 01; 139(7):2367-75. PubMed ID: 2958547
    [Abstract] [Full Text] [Related]

  • 5. Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen.
    Temponi M, Gold AM, Ferrone S.
    Cancer Res; 1992 May 01; 52(9):2497-503. PubMed ID: 1373670
    [Abstract] [Full Text] [Related]

  • 6. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity.
    Zapata G, Ridgway JB, Mordenti J, Osaka G, Wong WL, Bennett GL, Carter P.
    Protein Eng; 1995 Oct 01; 8(10):1057-62. PubMed ID: 8771187
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
    Tahtis K, Lee FT, Smyth FE, Power BE, Renner C, Brechbiel MW, Old LJ, Hudson PJ, Scott AM.
    Clin Cancer Res; 2001 Apr 01; 7(4):1061-72. PubMed ID: 11309358
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Inhibition of thrombocyte aggregation by F(ab')2-fragments of monoclonal antibodies FraMon (CRC64) to glycoproteins IIb-IIIa].
    Mazurov AV, Pevzner DV, Khaspekova SG, Dudnik OA, Byzova TV, Vlasik TN, Bakharev VN, Pistsov MIu, Staroverov II, Ruda MIa.
    Ter Arkh; 2001 Apr 01; 73(9):66-73. PubMed ID: 11642086
    [Abstract] [Full Text] [Related]

  • 15. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA, Goldman RC, Hammer CH, Leive L, Frank MM.
    J Immunol; 1983 Nov 01; 131(5):2563-9. PubMed ID: 6355296
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
    Covell DG, Barbet J, Holton OD, Black CD, Parker RJ, Weinstein JN.
    Cancer Res; 1986 Aug 01; 46(8):3969-78. PubMed ID: 3731067
    [Abstract] [Full Text] [Related]

  • 17. Improved tumor targeting with chemically cross-linked recombinant antibody fragments.
    King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson AD, Beeley NR.
    Cancer Res; 1994 Dec 01; 54(23):6176-85. PubMed ID: 7954464
    [Abstract] [Full Text] [Related]

  • 18. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.
    Better M, Bernhard SL, Lei SP, Fishwild DM, Lane JA, Carroll SF, Horwitz AH.
    Proc Natl Acad Sci U S A; 1993 Jan 15; 90(2):457-61. PubMed ID: 7678457
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK.
    Q J Nucl Med; 1998 Dec 15; 42(4):225-41. PubMed ID: 9973838
    [Abstract] [Full Text] [Related]

  • 20. Covalent modifications of antitetanus F(ab')2 fragments with natural and synthetic polyamines and their effects on the antibody endocytosis in cultured HL60 cells.
    Hervé F, Ghinea N, D'Athis P, Carrupt PA, Scherrmann JM.
    Bioconjug Chem; 2008 Aug 15; 19(8):1543-55. PubMed ID: 18630939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.